Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.

Scott E Kasner, Balakumar Swaminathan, Pablo Lavados, Mukul Sharma, Keith Muir, Roland Veltkamp, Sebastian F Ameriso, Matthias Endres, Helmi Lutsep, Steven R Messé, J David Spence, Krassen Nedeltechev, Kanjana Perera, Gustavo Santo, Veronica Olavarria, Arne Lindgren, Shrikant Bangdiwala, Ashkan Shoamanesh, Scott D Berkowitz, Hardi MundlStuart J Connolly, Robert G Hart

Research output: Contribution to journalOriginal Article (Journal)peer-review

118 Citations (Web of Science)
Original languageEnglish
Pages (from-to)1053-1060
JournalLANCET NEUROLOGY
Volume17
Issue number12
DOIs
Publication statusPublished - 2018

Keywords

  • CRYPTOGENIC STROKE
  • ISCHEMIC-STROKE
  • TRANSCATHETER CLOSURE
  • ANTIPLATELET THERAPY
  • MEDICAL THERAPY
  • METAANALYSIS
  • RISK

Cite this